RT Journal Article
SR Electronic
T1 Longer interval between maternal RSV vaccination and birth increases placental transfer efficiency
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.14.24310390
DO 10.1101/2024.07.14.24310390
A1 Jasset, Ms. Olyvia J.
A1 Andrea Lopez Zapana, Paola
A1 Bahadir, Zeynep
A1 Shook, Lydia
A1 Dennis, Ms. Maria
A1 Gilbert, Ms. Emily
A1 Liu, Ms. Zhaojing Ariel
A1 Yinger, Ms. Rachel V.
A1 Bald, Ms. Caroline
A1 Bradford, Ms. Caroline G.
A1 Silfen, Ms. Alexa H.
A1 Klein, Sabra L.
A1 Pekosz, Andrew
A1 Permar, Sallie
A1 Konnikova, Liza
A1 Yonker, Lael M.
A1 Lauffenburger, Douglas
A1 Nelson, Ashley
A1 Elovitz, Michal A.
A1 Edlow, Andrea G.
YR 2024
UL http://medrxiv.org/content/early/2024/07/15/2024.07.14.24310390.abstract
AB Background Respiratory Syncytial Virus (RSV) is associated with significant neonatal and infant morbidity and mortality. Maternal bivalent RSVpreF RSV vaccination to protect neonates and infants was approved in September 2023 for administration between 32+0 and 36+6 weeks to protect neonates and infants. This approved timeframe is narrower than the 24-36 week window evaluated in the clinical trial, due to the possible association between preterm birth and vaccine administration. Currently, data are lacking on how maternal vaccine timing within the approved window affects the transfer of antibodies from mother to fetus, critical information that could influence clinical practice.Objectives We sought to examine how gestational age at vaccination and time elapsed from maternal RSV vaccination to delivery impacted transfer of maternal antibodies measured in the umbilical cord at delivery and in peripheral blood of 2-month infants. We also examined differences in maternal and cord RSV antibody levels achieved by vaccination versus natural RSV infection.Study Design A prospective cohort study was conducted at two academic medical centers between September 20, 2023 and March 21, 2024, enrolling 124 individuals who received the RSV vaccine during pregnancy. Infant capillary blood was collected at 2 months of age from 29 of the infants. Maternal and cord IgG levels achieved by RSV vaccination were compared to those associated with maternal natural RSV infection, using banked blood from 20 maternal:cord dyads collected prior to the availability of the maternal RSV vaccine. Levels of IgG against RSV strain A2 and B fusion (F) and attachment (G) proteins and against pertussis toxin (as a comparator antigen from a vaccine routinely administered earlier in pregnancy) were measured using a Binding Antibody Multiplex Assay. Differences in titers between vaccination and natural infection were examined using Wilcoxon rank sum test. Differences in cord:maternal transfer ratios and 2-month infant antibody levels by timing of maternal vaccination were evaluated by Kruskal-Wallis testing.Results Maternal RSV vaccination resulted in significantly higher maternal and cord anti-F RSV antibody levels than natural infection (5.72 vs 4.82 log10MFI, p < 0.0001 maternal; 5.81 vs 5.03 log10MFI, p < 0.0001 cord). Maternal vaccination 2-3 weeks and 3-4 weeks prior to delivery was associated with significantly lower cord:maternal transfer ratios than were observed when vaccination occurred > 5 weeks prior to delivery (p = 0.03 for 2-3 weeks, p = 0.007 for 3-4 weeks), and significantly lower transfer ratios than observed for pertussis vaccination administered prior to 30 weeks’ gestation (p = 0.008 for 2-3 weeks, p = 0.03 for 3-4 weeks, similar at > 4 weeks).Conclusion(s) Vaccine administration earlier in the approved 32-36 week window (at least 5 weeks prior to delivery) results in the highest transplacental transfer of maternal antibodies to the neonate. These results should inform the counseling of pregnant individuals on optimal vaccination timing.Competing Interest StatementDisclosure statement: Outside of this work, A.G.E. serves as a consultant for Mirvie, Inc. and is a consultant for and has received research funding from Merck Pharmaceuticals. M.A.E serves as a consultant and has an equity interest in Mirvie.Funding StatementThis work was funded by NIH/NIAID: 1U19AI167899 to A.G.E., M.A.E. D.L and R01AI171980 to L.K; NIH/ NICHD 5K12HD103096 to L.L.S; NIH/NHLBI: R01HL173059 to L.Y.; MGH ECOR: MGH Research Scholar Award to A.G.E., Claflin Award to L.L.S.; Binational Science Foundation Award number 2019075 to L.K. None of the funders had any role in the design of the study; in the collection, analysis and interpretation of data; in the writing of the report; nor in the decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:MassGeneral Brigham IRB #s 2023P001874, 2020P003538, and 2020P000955 of MassGeneral Brigham gave ethical approval for this work. Mount Sinal School of Medicine IRB # 23-01383 of Icahn School of Medicine at Mount Sinai gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors